# Discordant Perioperative Prophylaxis and Major Morbidity After Pancreatoduodenectomy in Patients Undergoing PTBD: A Culture-Based Analysis

**Authors:** Yusuf Yunus Korkmaz, Feyyaz Gungor, Ilyas Kudas, Talha Sarigoz, Birkan Bozkurt, Ozgur Bostanci, Erdem Kinaci

PMC · DOI: 10.3390/jcm15062280 · Journal of Clinical Medicine · 2026-03-17

## TL;DR

This study examines whether mismatched antibiotic use based on bile cultures in patients undergoing pancreatoduodenectomy after biliary drainage affects postoperative complications.

## Contribution

The study introduces a novel framework for evaluating perioperative antibiotic adequacy using bile culture data and resistance profiles.

## Key findings

- Bile culture positivity and resistance severity were not independently linked to major postoperative morbidity.
- Discordant prophylaxis showed a trend toward increased major morbidity but did not reach statistical significance.
- Microbiological variables added little predictive value to clinical models of postoperative outcomes.

## Abstract

Background: Patients undergoing pancreatoduodenectomy (PD) after preoperative percutaneous transhepatic biliary drainage (PTBD) frequently develop bacterobilia. While bile culture positivity has been variably linked to postoperative infections, the clinical relevance of culture data may be more closely related to perioperative antimicrobial adequacy. We aimed to evaluate whether discordant perioperative antibiotic prophylaxis—defined by mismatch between administered prophylaxis and resistance profiles from preoperative PTBD bile cultures—is independently associated with major postoperative morbidity. Methods: This retrospective cohort study included consecutive patients undergoing PD between January 2020 and October 2025. Major morbidity (primary endpoint) was defined as Clavien–Dindo grade ≥ III. Secondary outcomes included postoperative day 4 inflammatory markers (WBC and CRP), length of stay, and infection-related endpoints. Bile culture findings were categorized by culture status and resistance severity (no growth, low resistance, and high resistance [MDR/XDR/PDR]). Discordant prophylaxis was defined using a predefined coverage-based algorithm incorporating antimicrobial class and susceptibility profiles. Multivariable logistic regression (adjusted for age, dichotomized ASA class, and operative type) and model performance (AUC, DeLong test; Hosmer–Lemeshow calibration) were assessed. Results: A total of 145 patients were analyzed; preoperative bile culture status was no culture (n = 30), culture-negative (n = 59), and culture-positive (n = 56). Bile culture status was not associated with major morbidity (p = 0.406), POD4 inflammatory markers, or length of stay. Resistance severity categories were also not associated with major morbidity (15.3%, 17.4%, and 24.2% across no-growth, low-resistance, and high-resistance groups, respectively; p = 0.77). Discordant prophylaxis occurred in 23 patients (15.9%) and was associated with higher major morbidity compared with concordant coverage (30.4% vs. 18.0%; OR: 1.99, 95% CI: 0.69–5.36; p = 0.25). After adjustment, discordant prophylaxis showed a higher point estimate for major morbidity (adjusted OR: 1.84, 95% CI: 0.63–4.96; p = 0.24), although this did not reach statistical significance. The core clinical model showed poor discrimination (AUC 0.59); adding microbiological variables modestly increased the AUC to 0.63 without significant improvement (DeLong p = 0.46). Model calibration was acceptable (Hosmer–Lemeshow p = 0.88). Conclusions: In this PTBD cohort undergoing PD, bile culture positivity and resistance severity were not independently associated with major postoperative morbidity. Discordant prophylaxis was associated with a numerical increase in major morbidity; however, this finding did not reach statistical significance and should be interpreted cautiously given the limited sample size. These findings support interpreting bile culture data primarily within an antimicrobial stewardship framework to ensure adequate coverage rather than as standalone predictors of severe morbidity and warrant validation in larger prospective cohorts.

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}
- **Diseases:** inflammatory (MESH:D007249), infection (MESH:D007239)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13026553/full.md

## References

31 references — full list in the complete paper: https://tomesphere.com/paper/PMC13026553/full.md

---
Source: https://tomesphere.com/paper/PMC13026553